1,721,162 research outputs found
Gemcitabine (dFdC) and 5 fluorouracil (5FU) in the treatment of patients with pancreas and colo-rectal carcinoma: a Clinical and pharmacological study.
No full textThe Optimal Choice of Local Therapy for Stage IIIA-N2 NSCLC: Is Radiotherapy Inferior to Surgery?
No full textGemcitabine plus Oxaliplatin Folinic Acid and 5-Fluorouracil in patients with advanced gastric cancer
No full textBACKGROUND AND AIMS:
oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer.
METHODS:
we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on days 1 and 2), a 5-FU (400 mg/m2) bolus injection followed by 22-h continuous infusion (800 mg/m2) on days 1 and 2, and oxaliplatin 85 mg/m2 in a 4-6 h intravenous (i.v.) infusion before the second FUFA administration on day 2.
RESULTS:
the most frequent side effect was grade 1-2 hematological toxicity and late sensorial neurotoxicity. Two patients developed hypersensitivity to oxaliplatin while another developed an aseptic eosinophilic pneumonitis. Two patients refused to continue the treatment after two cycles of chemotherapy and were lost at the follow-up. Among the remaining 34 patients four achieved a complete response, 15 a partial response, 12 had a stable disease and three progressed.
CONCLUSIONS:
these results may grant the rationale to evaluate this multi-drug combination in randomized phase III trials in advanced gastric cancer
Immunomodulatory properties of anticancer monoclonal antibodies: Is the 'magic bullet' still a reliable paradigm?
No full textRecruitment of dendritic cells and enhanced antigen specific immunoreactivity in cancer patients treated with Granulocyte Monocyte -Colony stimulating Factor and hrInterleukin -2: results from a phase I-II clinical trial.
No full text5th International Symposium on Predictive Oncology and Therapy. Geneva, Switzerland Oct. 28-3
Recruitment of bone marrow derived dendritic cells (DC) in cancer patients treated with hrGM-CSF and hrIL-2.
No full textGemcitabine plus oxaliplatin, folinic acid and infusional 5-fluorouracil (Oxali- FUFA) in patients with advanced gastric cancer
No full textImmunologic microenvironment and personalized treatment in multiple myeloma
No full textIntroduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased susceptibility to infections and secondary malignancies. Malignant plasma cells (PCs) modulate the bone marrow microenvironment to favor their own survival and proliferation. These events lead to a severe deregulation of immune effectors. Extensive studies have been conducted to unveil the mechanisms through which MM cells negatively modulate immunity and to develop therapeutical approaches for restoring an efficient anti-MM immune response. Areas covered: This review article covers both the immunosuppressive effects exerted by MM and the immunomodulatory potential of novel anti-MM agents. A brief overview on the most promising immunotherapeutic approaches in the field is also provided. Expert opinion: MM leads to a progressive impairment of the immune system. Different approaches have been evaluated or are currently under investigation to boost a specific anti-MM immune response. The discovery that anti-MM agents like bortezomib also retain immunomodulatory properties provides evidence to support the development of combined treatment modalities. In the next future, immunotherapy will be likely included in selective treatments in early stages or in the post-transplantation setting with non toxic modalities that control or clear the neoplastic clone. © 2013 Informa UK, Ltd
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities
Full text linkImmunosuppressive cells have been reported to play an important role in tumor progression mainly because of their capability to promote immuneescape, angiogenesis and metastasis. Among them, myeloid derived suppressor cells (MDSCs) have been recently identified as immature myeloid cells, induced by tumor-associated inflammation, able to impair both innate and adaptive immunity. While murine MDSCs are usually identified by the expression of CD11b and Gr-1, human MDSCs represent a more heterogeneous population characterized by the expression of CD33 and CD11b, low or no HLA-DR and variable CD14 and CD15. In particular, the last two may alternatively identify monocyte-like or granulocyte-like MDSC subsets with different immunosuppressive properties. Recently, a substantial increase of MDSCs has been found in peripheral blood and bone marrow (BM) of multiple myeloma (MM) patients with a role in disease progression and/or drug resistance. Preclinical models recapitulating the complexity of the MM-related BM microenvironment (BMM) are major tools for the study of the interactions between MM cells and cells of the BMM (including MDSCs) and for the development of new agents targeting MM-associated immune suppressive cells. This review will focus on current strategies for human MDSCs generation and investigation of their immunosuppressive function in vitro and in vivo, taking into account the relevant relationship occurring within the MM-BMM. We will then provide trends in MDSC-associated research and suggest potential application for the treatment of MM
- …
